Assay News and Research

RSS

UCI researchers develop noninvasive, at-home saliva test to detect COVID-19

Researchers in the Henry Samueli School of Engineering at the University of California, Irvine announced promising results in the development of a noninvasive at-home antigen test to detect the spike of SARS-CoV-2 proteins in saliva.

9 Dec 2020

Study suggests vast majority of Seattle population remains susceptible to COVID-19

Researchers in the United States have conducted a study suggesting that a small proportion of people living in Seattle were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – by around late March/early April 2020.

9 Dec 2020

Different SARS-CoV-2 neutralization assays are reliable and concordant for antibody monitoring

A recent study by US researchers, currently available on the medRxiv preprint server, evaluated several cell-based assays that are under validation for determining correlates of protection in individuals with symptomatic coronavirus disease (COVID-19) and vaccine studies – and demonstrated their high concordance with both live and pseudotyped virions.

9 Dec 2020

Amilorides reduce SARS-CoV-2 viral replication in vitro

A new U.S. study published on the bioRxiv preprint server reports the use of an amiloride-based scaffold that targets a viral RNA structure known to be essential in viral replication in the 5’-untranslated region (UTR) of the virus. The researchers say this heralds the application of these molecules as chemical probes to explore viral biology and produce specific antivirals targeting RNA regions of the coronavirus genome.

8 Dec 2020

High-performing multi-immunoassay for early diagnosis and prognosis of COVID-19

A new study published on the preprint server bioRxiv in December 2020 indicates the ability of anti-SARS-CoV-2 antibody titers and time of induction to differentiate between severe and mild COVID-19 and could lead to the development of a prognostic biomarker for use early in the course of the illness.

8 Dec 2020

Lipid storm in severe COVID-19 linked to high COX/LOX pathway activity

A potentially valuable new study discusses the role of lipids in the hyper-inflammatory phenomena that take place within the lungs of patients with severe or critical COVID-19. Involving a large variety of specialized lipids with biological activity, this process includes the generation and release of pro and anti-inflammatory lipids.

8 Dec 2020

UCI researchers develop new technology to rapidly hypermutate antibodies

Using the same strain of yeast that ferments wine and makes dough rise, a team led by University of California, Irvine and Harvard Medical School researchers has developed an in vitro technology that can rapidly hypermutate antibodies.

8 Dec 2020

Potential SARS-CoV-2 Mpro inhibitors identified by in silico screening

The search for effective inhibitors of SARS-CoV-2 is assuming new urgency as the fall/winter resurgence of the infection appears.

7 Dec 2020

STE90-C11, a SARS-CoV-2 neutralizing antibody, shows high inhibition of RBD-ACE2 binding

In a new study, researchers describe the identification of a neutralizing antibody that binds to the RBD at the same site as the human host cell receptor.

7 Dec 2020

High-performance ELISA for serology in mild-moderate non-hospitalized COVID-19

A new study describes an ELISA assay that combines the detection of IgM, IgA, and IgG antibodies against the SARS−CoV−2 trimeric spike glycoprotein.

7 Dec 2020

CRISPR-based test could provide rapid, low-cost testing to help control COVID-19 spread

Imagine swabbing your nostrils, putting the swab in a device, and getting a read-out on your phone in 15 to 30 minutes that tells you if you are infected with the COVID-19 virus.

5 Dec 2020

Mysterious particle found in the blood of people with sepsis

Researchers at La Jolla Institute for Immunology have found that people with sepsis have never-before-seen particles in their blood.

5 Dec 2020

SARS-CoV-2 D614G mutation does not affect performance of serological assays

In a new study published in The Journal of Infectious Diseases, US researchers considered the emergence of a new SARS-CoV-2 spike protein variant. They compared spike G614-based assay to the original D614-based assay – pointing towards the development of recognizable, cross-responsive humoral immunity.

2 Dec 2020

SARS-CoV-2 deletion mutations may have attenuated infectivity in some strains

A team of researchers at the University of Hong Kong has identified a panel of SARS-CoV-2 variants, called Del-mut, which contains a deletion in the S1/S2 junction. Upon investigating one of the deleted variants in animal models, they found that Del-mut-1 is attenuated in its ability to cause disease or pathological changes.

2 Dec 2020

Potential SARS-CoV-2 antiviral: Ionophore X-206 found to inhibit viral replication in cell cultures

In a study published in the journal Antiviral Research, researchers from Aarhus University, Denmark, report on their tests on different polyether ionophores to inhibit SARS-CoV-2 in vitro.

1 Dec 2020

Good cholesterol helps SARS-CoV-2 enter cells

The researchers explained that the SARS-CoV-2 can infect human host cells after its viral spike protein (SARS-2-S) binds to a cellular surface receptor called the angiotensin-converting enzyme 2 (ACE2).

30 Nov 2020

Chemical compounds in foods can block the function of key SARS-CoV-2 enzyme

Chemical compounds in foods or beverages like green tea, muscadine grapes and dark chocolate can bind to and block the function of a particular enzyme, or protease, in the SARS-CoV-2 virus, according to a new study by plant biologists at North Carolina State University.

30 Nov 2020